Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Lu, J
  • Deng, H
  • Tang, R
  • Hsu, C
  • Kindler, HL
  • Fuchs, CS
  • Gansert, JL
  • Bray, Steven
  • Suzuki, SS
  • Loh, E
  • Zhu, M

publication date

  • May 20, 2011